SignalXSignalX

Monopar Therapeutics (MNPR) 8-K Current Report — March 2, 2026

Filed: March 2, 2026
Health Care
Pharmaceutical Preparations
Monopar Therapeutics Overview

Monopar Therapeutics (MNPR) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 7.01: Regulation FD Disclosure

Monopar Therapeutics 8-K Mar 2, 2026 Event Analysis

Item 7.01 · Regulation FD Disclosure

  • • Susan Rodriguez appointed Chief Commercial and Strategy Officer at Monopar Therapeutics, effective March 2, 2026
  • • New C-suite role signals commercial buildout phase — typically precedes or accompanies product launch preparations
+1 more insights

Get deeper insights on Monopar Therapeutics

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.